Liyu Wu
Global Vice President, Business Development LIDE Biotech
Seminars
Tuesday 13th October 2026
Beyond the Antigen: Exploring a Translational Platform for ADC Evaluation & Next-Generation Target Discovery
12:30 pm
- Evaluating how a Mouse Clinical Trial converts preclinical efficacy into a clinically shaped ORR readout, illustrated with a HER2 ADC case study
- Utilizing a payload-resistant model to reveal that resistance tracks with payload mechanism, largely independently of target antigen, reframing how backup and next-generation ADCs should be triaged
- Carrying out functional omics screens in vivo inside low-passage patient-derived tumors for novel ADC target discovery, validated on our own pipeline
